

BOSTON SCIENTIFIC CORP  
Form 8-K  
December 11, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

December 10, 2009

**Boston Scientific Corporation**

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

One Boston Scientific Place, Natick,  
Massachusetts

01760-1537

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

508-650-8000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 8.01 Other Events.**

On December 10, 2009, we announced the pricing of a public offering of \$2 billion aggregate principal amount of our senior notes under our shelf registration statement. The public offering consists of \$850 million of 4.50 percent notes due January 2015, \$850 million of 6.00 percent notes due January 2020 and \$300 million of 7.375 percent notes due January 2040. We expect the offering to close on December 14, 2009, subject to standard closing conditions. We plan to use the net proceeds for general corporate purposes, including prepaying a portion of our bank term loan due in April 2011. We expect to record a pre-tax charge, not previously anticipated, of approximately \$30 million (approximately \$19 million after tax, or \$0.01 per share) in the fourth quarter associated with the prepayment.

A copy of the press release is filed with this report as Exhibit 99.1.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Boston Scientific Corporation

*December 11, 2009*

By: *Lawrence J. Knopf*

---

*Name: Lawrence J. Knopf*

*Title: Senior Vice President and Deputy General Counsel*

---

**Top of the Form**

Exhibit Index

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Boston Scientific Corporation dated December 10, 2009.